14. Abbott - Top 15 R&D Budgets

Who: Abbott

Based: United States

2006 Pipeline Budget: $2.5 billion (€1.71 billion)

2007 Pipeline News: Abbott doesn't post its pipeline, but according to information on clinicaltrials.gov, the company is currently running Phase III trials for additional indications for its blockbuster anti-TNF drug Humira. The company has four other compounds in Phase III and no drug pending FDA approval.

Phase III Pipeline:

> Adalimumab (Humira) - Rheumatoid Arthritis, Crohn's Disease, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile RA, Ulcerative Colitis, Uveitis, Giant Cell Arteritis
> Levosimendan - Congestive heart failure, Acute Heart Failure, Cardiogenic Shock, Septic Shock
> ABT-335 androsuvastatin calcium - Hypercholesterolemia, Dyslipidemia
> Atrasentan - Cancer, Prostatic Neoplasms
> Pricalcitol - Chronic Renal Insufficiency

Full Pipeline Site: See clinicaltrials.gov

14. Abbott - Top 15 R&D Budgets

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.